KR101911105B1 - 제약 조성물 - Google Patents

제약 조성물 Download PDF

Info

Publication number
KR101911105B1
KR101911105B1 KR1020137004494A KR20137004494A KR101911105B1 KR 101911105 B1 KR101911105 B1 KR 101911105B1 KR 1020137004494 A KR1020137004494 A KR 1020137004494A KR 20137004494 A KR20137004494 A KR 20137004494A KR 101911105 B1 KR101911105 B1 KR 101911105B1
Authority
KR
South Korea
Prior art keywords
methyl
cancer
hydrogen
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137004494A
Other languages
English (en)
Korean (ko)
Other versions
KR20130099008A (ko
Inventor
마크 스파이비
타카시 사토
조나단 에릭 칼슨
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20130099008A publication Critical patent/KR20130099008A/ko
Application granted granted Critical
Publication of KR101911105B1 publication Critical patent/KR101911105B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137004494A 2010-09-21 2011-09-12 제약 조성물 Active KR101911105B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38478110P 2010-09-21 2010-09-21
US61/384,781 2010-09-21
PCT/US2011/051163 WO2012039972A1 (en) 2010-09-21 2011-09-12 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
KR20130099008A KR20130099008A (ko) 2013-09-05
KR101911105B1 true KR101911105B1 (ko) 2018-10-23

Family

ID=44674894

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137004494A Active KR101911105B1 (ko) 2010-09-21 2011-09-12 제약 조성물

Country Status (31)

Country Link
US (2) US8686018B2 (enExample)
EP (2) EP2619182B1 (enExample)
JP (1) JP5956448B2 (enExample)
KR (1) KR101911105B1 (enExample)
CN (1) CN103097358B (enExample)
AU (1) AU2011305872B2 (enExample)
BR (1) BR112013002484B1 (enExample)
CA (1) CA2806121C (enExample)
CL (1) CL2013000675A1 (enExample)
CY (1) CY1118680T1 (enExample)
DK (1) DK2619182T3 (enExample)
ES (1) ES2610185T3 (enExample)
HR (1) HRP20170042T1 (enExample)
HU (1) HUE031408T2 (enExample)
IL (1) IL224288A (enExample)
LT (1) LT2619182T (enExample)
ME (1) ME02575B (enExample)
MX (1) MX2013003162A (enExample)
MY (1) MY162146A (enExample)
NZ (1) NZ606629A (enExample)
PE (1) PE20131343A1 (enExample)
PH (1) PH12013500467A1 (enExample)
PL (1) PL2619182T3 (enExample)
PT (1) PT2619182T (enExample)
RS (1) RS55566B1 (enExample)
RU (1) RU2606510C2 (enExample)
SG (1) SG188188A1 (enExample)
SI (1) SI2619182T1 (enExample)
SM (2) SMT201700008T1 (enExample)
UA (1) UA113499C2 (enExample)
WO (1) WO2012039972A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
SG11201510121RA (en) 2013-06-12 2016-01-28 Kaken Pharma Co Ltd 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
CN106572993B (zh) 2014-05-23 2019-07-16 卫材R&D管理有限公司 Ep4拮抗剂在制备治疗癌症的药物中的应用
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
CN108368127B (zh) 2015-07-23 2020-12-11 武田药品工业株式会社 化合物及其作为ep4受体拮抗剂的用途
US10316040B2 (en) * 2015-10-16 2019-06-11 Eisai R&D Management Co., Ltd. EP4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
LT3625224T (lt) 2017-05-18 2021-10-25 Idorsia Pharmaceuticals Ltd N-pakeistieji indolo dariniai
PT3625228T (pt) 2017-05-18 2021-09-16 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores dos recetores de pge2
LT3625222T (lt) 2017-05-18 2021-11-10 Idorsia Pharmaceuticals Ltd Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
CN108929281B (zh) * 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
EP3749323A4 (en) * 2018-02-05 2021-11-03 Shenzhen Ionova Life Science Co., Ltd. HETEROBICYCLIC CARBOXYLIC ACIDS TO TREAT CANCER OR INFLAMMATORY DISEASES
AU2021229414B2 (en) * 2020-03-04 2023-07-06 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Synthesis of novel EP4 antagonist and use in cancers and inflammations
WO2022037601A1 (zh) * 2020-08-18 2022-02-24 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
JPWO2022102731A1 (enExample) 2020-11-13 2022-05-19
TWI877433B (zh) 2020-11-30 2025-03-21 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
CN116801879B (zh) * 2021-01-28 2025-09-26 深圳众格生物科技有限公司 吡唑酰胺衍生物及其制备方法和应用
CN115745892A (zh) * 2021-09-03 2023-03-07 武汉人福创新药物研发中心有限公司 一种ep4拮抗剂化合物及其盐、多晶型和用途
CN115364222A (zh) * 2021-09-09 2022-11-22 首都医科大学附属北京地坛医院 Ep4受体抑制剂治疗肝纤维化的应用
EP4452949A1 (en) 2021-12-23 2024-10-30 Eisai R&D Management Co., Ltd. Crystalline salt form of ep4 antagonist
US20250381143A1 (en) * 2021-12-30 2025-12-18 Adlai Nortye Biopharma Co., Ltd. A solid pharmaceutical composition
WO2024027599A1 (zh) * 2022-08-04 2024-02-08 杭州阿诺生物医药科技有限公司 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0421671A (ja) * 1990-05-16 1992-01-24 Mitsubishi Kasei Corp ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
FR2847160A1 (fr) 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
HRP20110757T1 (hr) * 2003-06-26 2011-11-30 Novartis Ag Inhibitori kinaze p38 bazirani na 5-članom heterociklu
AP2006003534A0 (en) 2003-09-03 2006-04-30 Pfizer Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
GT200500013A (es) 2004-01-23 2005-08-10 Amidas herbicidas
BRPI0510666A (pt) * 2004-05-04 2007-12-04 Pfizer compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
JP4054369B2 (ja) * 2004-05-04 2008-02-27 ファイザー株式会社 オルト置換アリールまたはヘテロアリールアミド化合物
WO2006132197A1 (ja) 2005-06-07 2006-12-14 Shionogi & Co., Ltd. I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
EP1891048A1 (en) * 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
EP1953145B1 (en) 2005-11-21 2015-11-04 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-b-hydroxysteroid dehydrogenase type i
WO2007091570A1 (ja) * 2006-02-06 2007-08-16 Taisho Pharmaceutical Co., Ltd. スフィンゴシン－１－リン酸結合阻害物質
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
EP2054401B1 (en) 2006-08-11 2013-05-01 Merck Canada Inc. Thiophenecarboxamide derivatives as ep4 receptor ligands
JP5069752B2 (ja) 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
WO2008104055A1 (en) 2007-02-26 2008-09-04 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
US7560936B1 (en) 2007-04-24 2009-07-14 Integrated Device Technology, Inc. Method and apparatus for ground bounce and power supply bounce detection
BRPI0812958A2 (pt) 2007-06-15 2014-12-09 Basf Se Processo para preparar compostos, uso de compostos, e, compostos
US20110028463A1 (en) 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
ES2551095T3 (es) 2007-07-19 2015-11-16 Lundbeck, H., A/S Amidas heterocíclicas de 5 miembros y compuestos relacionados
CL2008002241A1 (es) 2007-07-31 2009-12-28 Bayer Cropscience Sa Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas.
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
JP2011529866A (ja) 2008-08-01 2011-12-15 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト 殺菌剤ｎ−シクロアルキル−ｎ−ビフェニルメチル−カルボキサミド誘導体
US8404736B2 (en) * 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
JP2012503605A (ja) 2008-09-25 2012-02-09 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのベータ−カルボリンスルホニルウレア誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists

Also Published As

Publication number Publication date
PH12013500467A1 (en) 2013-04-29
AU2011305872B2 (en) 2015-03-26
BR112013002484B1 (pt) 2021-10-13
LT2619182T (lt) 2017-01-25
NZ606629A (en) 2015-03-27
US8686018B2 (en) 2014-04-01
ME02575B (me) 2017-06-20
KR20130099008A (ko) 2013-09-05
DK2619182T3 (en) 2017-01-30
ES2610185T3 (es) 2017-04-26
US9000024B2 (en) 2015-04-07
SMT201700008T1 (it) 2017-03-08
EP2619182B1 (en) 2016-11-09
MX2013003162A (es) 2013-05-06
MY162146A (en) 2017-05-31
JP2013538825A (ja) 2013-10-17
JP5956448B2 (ja) 2016-07-27
CA2806121C (en) 2018-10-09
PE20131343A1 (es) 2013-11-18
US20140155452A1 (en) 2014-06-05
CL2013000675A1 (es) 2013-07-05
SI2619182T1 (sl) 2017-03-31
HUE031408T2 (en) 2017-07-28
CA2806121A1 (en) 2012-03-29
CN103097358B (zh) 2015-04-08
WO2012039972A1 (en) 2012-03-29
SMT201700008B (it) 2017-03-08
IL224288A (en) 2015-02-26
AU2011305872A1 (en) 2013-01-31
US20130237578A1 (en) 2013-09-12
BR112013002484A2 (pt) 2016-05-31
RS55566B1 (sr) 2017-05-31
PT2619182T (pt) 2017-01-17
PL2619182T3 (pl) 2017-03-31
RU2606510C2 (ru) 2017-01-10
SG188188A1 (en) 2013-04-30
EP3061751A1 (en) 2016-08-31
CY1118680T1 (el) 2017-07-12
UA113499C2 (xx) 2017-02-10
CN103097358A (zh) 2013-05-08
HRP20170042T1 (hr) 2017-03-10
EP2619182A1 (en) 2013-07-31
RU2013118209A (ru) 2014-10-27

Similar Documents

Publication Publication Date Title
KR101911105B1 (ko) 제약 조성물
WO2012103071A2 (en) Compounds and compositions
RU2627268C2 (ru) Аза-арил-1Н-пиразол-1-ил-сульфонамиды
KR101593237B1 (ko) 5-원 헤테로시클릭 아미드 및 관련 화합물
KR101589332B1 (ko) ２ｈ-크로멘 화합물 및 그의 유도체
JP7034512B2 (ja) キナーゼ阻害剤としてのヘテロアリール化合物
WO2023016484A1 (zh) 磺酰胺衍生物、其制备方法及其在医药上的应用
CN101636385B (zh) 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
CN108929281B (zh) 三氮唑类化合物及其合成方法和应用
JP2022549601A (ja) ヘテロアリール血漿カリクレインインヒビター
JP2015531395A (ja) ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
CN108779100A (zh) 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用
HK1181765A (en) Pharmaceutical composition
HK1181765B (en) Pharmaceutical composition
WO2008020606A1 (en) Antiangiogenic agent
AU2024320585A1 (en) Novel compound, and pharmaceutical composition for prevention or treatment of cancer or tumors comprising same
US20240294522A1 (en) 3-substituted 1h-pyrrolo[2,3-b]pyridine as grk5 modulators
HK1261495A1 (en) 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8